Lunit said it signed a strategic partnership with France’s largest private imaging network, Groupe Vidi, to supply its AI-based mammography screening solution, Lunit INSIGHT MMG.

Groupe Vidi operates over 400 medical facilities across France with more than 1,200 radiology professionals, processing around 10 million imaging tests annually and holding a 23 percent market share in France’s private imaging sector.

This collaboration traces back to 2021, when select imaging centers within the Vidi network adopted Lunit’s AI solutions in clinical settings. At that time, Dr. François Pey from Coradix, a Vidi -affiliated imaging center, highlighted the solution’s effectiveness, stating that Lunit INSIGHT MMG “reduces diagnostic errors and helps identify potentially overlooked lesions accurately, thereby minimizing unnecessary follow-up imaging.”

Building on these positive results, Lunit and Vidi recently formalized their partnership at the French Radiology Congress 2024 (Journées Francophones de Radiologie 2024). As a result, Lunit INSIGHT MMG will now be listed as an official medical solution across the VIDI network, streamlining its adoption for the network's 400 medical facilities.

“This partnership aligns with Vidi ’s strategy to introduce innovative medical solutions early to improve the diagnostic process,” Vidi Director-General of Operations Amelie Libessart-Nory said. “Notably, with long waiting times in medical settings identified as a social issue, leveraging AI technology is expected to significantly enhance clinical efficiency.”

Lunit CEO Suh Beom-suk also said, “Breast cancer, which ranked as the leading cancer among French women in terms of incidence and mortality last year, had over 60,000 newly diagnosed cases.”

The partnership which combines Vidi ’s extensive medical network and Lunit’s AI technology promises a transformative impact on early detection and diagnostic efficiency for breast cancer, Suh added.